NYSE: JNJJohnson & Johnson Stock
$161.30+1.19 (+0.74%)
Updated Oct 15, 2021
JNJ Price
$161.30
Fair Value Price
N/A
Market Cap
$424.62B
52 Week Low
$133.65
52 Week High
$179.92
P/E
23.93x
P/B
6.1x
P/S
4.99x
PEG
1.33x
Dividend Yield
2.57%
Revenue
$89.19B
Earnings
$17.77B
Gross Margin
67%
Operating Margin
22.84%
Profit Margin
19.9%
Debt to Equity
1.54
Operating Cash Flow
$26B
Beta
0.65
Next Earnings
Oct 19, 2021
Ex-Dividend
N/A
Next Dividend
N/A
Zen Score
High
Medium
Low
47
Industry average
Reasons for this score
JNJ ($161.30) is trading below its intrinsic value of $500.57, according to Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Valuation
JNJ is poor value based on its earnings relative to its share price (23.93x), compared to the US market average (4.4x)
Valuation
JNJ is poor value based on its earnings relative to its share price (23.93x), compared to the US Drug Manufacturers - General industry average (22.54x)
Valuation
JNJ News
Valuation
JNJ price to earnings (PE)
For valuing profitable companies with steady earnings
Company
23.93x
Industry
22.54x
Market
4.4x
JNJ is poor value based on its earnings relative to its share price (23.93x), compared to the US market average (4.4x)
Valuation
JNJ is poor value based on its earnings relative to its share price (23.93x), compared to the US Drug Manufacturers - General industry average (22.54x)
Valuation
JNJ price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.1x
Industry
5.12x
JNJ is poor value based on its book value relative to its share price (6.1x), compared to the US Drug Manufacturers - General industry average (5.12x)
Valuation
JNJ price to earnings growth (PEG)
For valuing profitable companies with growth potential
JNJ is poor value relative to its rate of earnings growth, measured by PEG ratio (1.33x)
Valuation
JNJ's financial health
Profit margin
Revenue
$23.3B
Net Income
$6.3B
Profit Margin
26.9%
JNJ's Earnings (EBIT) of $20.37B can safely cover interest payments on company debt ($33.48B)
Financials
JNJ's profit margin has increased (+1%) in the last year from (18.9%) to (19.9%)
Financials
Assets to liabilities
Assets
$176.4B
Liabilities
$106.9B
Debt to equity
0.48
JNJ's short-term assets ($53.77B) exceed its short-term liabilities ($38.72B)
Financials
JNJ's long-term liabilities ($68.14B) exceed its short-term assets ($53.77B)
Financials
JNJ's debt has increased relative to shareholder equity (1.54), over the past 5 years ago (0.93)
Financials
JNJ's debt to equity ratio (1.54) is considered high
Financials
Cash flow
Operating
$5.3B
Investing
-$419.0M
Financing
-$3.3B
JNJ's operating cash flow ($26.11B) is sufficient to service the company's debt ($33.48B)
Financials
Johnson & Johnson Stock FAQ
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.